EP1487414A4 - Antibiotische zusammensetzung - Google Patents

Antibiotische zusammensetzung

Info

Publication number
EP1487414A4
EP1487414A4 EP03714005A EP03714005A EP1487414A4 EP 1487414 A4 EP1487414 A4 EP 1487414A4 EP 03714005 A EP03714005 A EP 03714005A EP 03714005 A EP03714005 A EP 03714005A EP 1487414 A4 EP1487414 A4 EP 1487414A4
Authority
EP
European Patent Office
Prior art keywords
antibiotic composition
antibiotic
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03714005A
Other languages
English (en)
French (fr)
Other versions
EP1487414A2 (de
Inventor
Edward M Rudnic
James D Isbister
Jr Donald J Treacy
Sandra E Wassink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MiddleBrook Pharmaceuticals Inc
Original Assignee
Advancis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/093,321 external-priority patent/US6610328B2/en
Priority claimed from US10/092,854 external-priority patent/US6627222B2/en
Priority claimed from US10/092,811 external-priority patent/US6623758B2/en
Priority claimed from US10/093,214 external-priority patent/US6638532B2/en
Priority claimed from US10/092,858 external-priority patent/US6632453B2/en
Application filed by Advancis Pharmaceutical Corp filed Critical Advancis Pharmaceutical Corp
Publication of EP1487414A2 publication Critical patent/EP1487414A2/de
Publication of EP1487414A4 publication Critical patent/EP1487414A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
EP03714005A 2002-03-07 2003-03-07 Antibiotische zusammensetzung Withdrawn EP1487414A4 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US93321 1993-07-16
US92854 1993-07-19
US10/093,321 US6610328B2 (en) 2000-02-24 2002-03-07 Amoxicillin-clarithromycin antibiotic composition
US92858 2002-03-07
US10/092,854 US6627222B2 (en) 2000-02-24 2002-03-07 Amoxicillin-dicloxacillin antibiotic composition
US10/092,811 US6623758B2 (en) 2000-02-24 2002-03-07 Cephalosporin-metronidazole antibiotic composition
US10/093,214 US6638532B2 (en) 2000-02-24 2002-03-07 Tetracycline—doxycycline antibiotic composition
US92811 2002-03-07
US10/092,858 US6632453B2 (en) 2000-02-24 2002-03-07 Ciprofoxacin-metronidazole antibiotic composition
US93214 2002-03-07
PCT/US2003/007118 WO2003075852A2 (en) 2002-03-07 2003-03-07 Antibiotic composition

Publications (2)

Publication Number Publication Date
EP1487414A2 EP1487414A2 (de) 2004-12-22
EP1487414A4 true EP1487414A4 (de) 2007-12-12

Family

ID=27808882

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03714005A Withdrawn EP1487414A4 (de) 2002-03-07 2003-03-07 Antibiotische zusammensetzung

Country Status (4)

Country Link
EP (1) EP1487414A4 (de)
JP (1) JP2005526059A (de)
CA (1) CA2478121A1 (de)
WO (1) WO2003075852A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
AUPS167602A0 (en) * 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
KR20080007586A (ko) * 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 세균감염증의 치료를 위한 세팔로스포린 함유 조절 방출조성물
JP2008540602A (ja) 2005-05-18 2008-11-20 ダ・ボルテラ 吸着剤の結腸送達
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
WO2009137672A1 (en) * 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062195A1 (en) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US20010046984A1 (en) * 2000-02-24 2001-11-29 Rudnic Edward M. Antibiotic composition with inhibitor
US20010048944A1 (en) * 2000-02-24 2001-12-06 Rudnic Edward M. Antibiotic product, use and formulation thereof
US20020013345A1 (en) * 1998-10-09 2002-01-31 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
JPS63162619A (ja) * 1986-12-25 1988-07-06 Teisan Seiyaku Kk 遅溶性顆粒及びそれを用いた持続性複合顆粒
NL8800223A (nl) * 1987-04-21 1988-11-16 Philips Nv Systeem voor het registreren van een informatiesignaal, alsmede een registratiedrager en registratieinrichting voor toepassing in het systeem.
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
WO1996010996A1 (en) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020013345A1 (en) * 1998-10-09 2002-01-31 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
WO2001062195A1 (en) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US20010046984A1 (en) * 2000-02-24 2001-11-29 Rudnic Edward M. Antibiotic composition with inhibitor
US20010048944A1 (en) * 2000-02-24 2001-12-06 Rudnic Edward M. Antibiotic product, use and formulation thereof

Also Published As

Publication number Publication date
AU2003218024A1 (en) 2003-09-22
AU2003218024B2 (en) 2008-09-11
JP2005526059A (ja) 2005-09-02
EP1487414A2 (de) 2004-12-22
WO2003075852A2 (en) 2003-09-18
CA2478121A1 (en) 2003-09-18
WO2003075852A3 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
IL163749A0 (en) Novel florfenicol-type antibiotics
AU2003285288A1 (en) Composition
EP1482957A4 (de) Antibiotische konjugate
GB0318894D0 (en) Composition
GB0203421D0 (en) Composition
AU2003235708A1 (en) Polytartrate composition
GB0227244D0 (en) Composition
GB0208608D0 (en) Composition
GB0203296D0 (en) Novel composition
GB0203280D0 (en) Anti-glycolytic composition
EP1487414A4 (de) Antibiotische zusammensetzung
GB0211924D0 (en) Composition
GB0218241D0 (en) Composition
GB0230274D0 (en) Composition
HK1082517A1 (en) Oil-barrier composition
EP1495751A4 (de) Haarfärbezusammensetzung
GB0315629D0 (en) New uses for antibiotic
GB0229286D0 (en) Composition
GB0205786D0 (en) Novel Composition
GB0213767D0 (en) Composition
GB0203616D0 (en) Composition
GB0301869D0 (en) Composition
GB0222729D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040930

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WASSINK, SANDRA, E.

Inventor name: TREACY, JR., DONALD, J.

Inventor name: ISBISTER, JAMES, D.

Inventor name: RUDNIC, EDWARD, M.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADVANCIS PHARMACEUTICAL CORPORATION

A4 Supplementary search report drawn up and despatched

Effective date: 20071114

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIDDLEBROOK PHARMACEUTICALS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MIDDLEBROOK PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001